Skip to main content
. 2014 Jan 24;22(6):1579–1584. doi: 10.1007/s00520-014-2132-4

Table 1.

Baseline characteristics of eligible patients

Non-OXY group x(N = 35) OXY group (N = 29)
Mean age (range) 64.9 (48–76) 62.7 (48–75)
Gender
 Male 19 16
 Female 17 13
Stage
 IIIA 1 0
 IIIB 4 2
 IIIC 7 2
 IV 23 25
Chemotherapy regimen
 mFOLFOX 28 9
 mFOLFOX + bevacizumab 7 18
 mFOLFOX + bevacizumab + panitumumab 0 2